Samumed completes phase I chronic tendinopathy study
Samumed, a leader in musculoskeletal conditions, announced the successful completion of a phase I clinical trial in healthy subjects for its potential treatment of chronic tendinopathy, a degenerative and fibrotic condition caused by injuries or overuse and that has no FDA-approved drug treatments today. The study results supported the continuation of the program into future studies in tendinopathy patients. There were no serious adverse events related to the drug (as deemed by the investigators) and a maximum tolerated dose was not reached in any of the three treatment groups. A detailed analysis, including safety and pK results, will be presented at a future medical conference.
Samumed’s investigational drug is a topical gel containing its novel small molecule compound SM04755. The study was a randomized, single-blind, placebo-controlled phase I trial studying the safety and tolerability of SM04755 applied daily for fourteen days to 23 healthy subjects, between the ages of 18 and 50. SM04755 was tested in three ascending dose levels in three different treatment groups, each with a placebo control. The study also examined the systemic exposure and pharmacokinetics of SM04755 following single and repeated doses.
Tendinopathy is the clinical diagnosis of pain, swelling, and impaired performance of the tendon, the tissue that connects muscle to bone. Tendinopathy can encompass both inflammation of the tendon (tendinitis) and degeneration of the tendon (tendinosis). Epicondylitis, or pain in the wrist extensor tendons in the elbow, affects 1 to 3% of the population, with 10% of cases refractory at 6 months progressing to surgery. The Achilles tendon at the ankle and the patellar tendon of the knee are also frequently affected. Current therapeutic options alleviate symptoms rather than treating underlying pathology of the disease.
Based in San Diego, California, Samumed is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation. Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.